Prognostic Value of Nicotinamide N-Methyltransferase Expression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis
Authors:
Open Access
- 8 October 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 9, 1407
Abstract
Background: Nicotinamide N-methyltransferase (NNMT) is an enzyme that catalyzes N-methylation of pyridine-containing compounds. NNMT is upregulated in many types of solid tumors, suggesting the potential for its use as a tumor biomarker. However, the prognostic value of NNMT in solid tumors is still unclear. We therefore conducted a meta-analysis to investigate the association between NNMT expression and survival in patients with solid tumors. Methods: We focused on patients with solid tumors, using high NNMT expression levels as the intervention and low NNMT expression levels as the comparison, according to Patient, Intervention, Comparison, and Outcome (PICO) guidelines. Electronic databases (up to June 7, 2018) were comprehensively searched to collect relevant cohort studies regarding the associations between NNMT expression levels and survival outcomes (overall survival [OS], disease-specific survival [DSS] including cancer-specific survival [CSS], and time to tumor progression [TTP] including disease-free survival [DFS], progression-free survival [PFS], and metastasis-free survival [MeFS]). Publication biases were also examined. All analyses were performed using STATA 12.0 software. Results: A total of 3340 patients with solid tumors from nine published studies were included. The combined hazard ratio (HR) identified high NNMT expression levels as a poor prognostic predictor of OS (HR = 1.67, 95% CI = 1.23–2.26). However, NNMT levels had no significant association with DSS (HR = 1.47, 95% CI = 0.95–2.28) and TTP (HR = 1.13, 95%CI = 0.39–3.25). Conclusion: High NNMT expression levels may be a poor prognostic biomarker for patients with solid tumors.Keywords
This publication has 24 references indexed in Scilit:
- Nicotinamide metabolism regulates glioblastoma stem cell maintenanceJCI Insight, 2017
- NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming AbilityClinical Cancer Research, 2017
- HDACs and HDAC Inhibitors in Cancer Development and TherapyCold Spring Harbor Perspectives in Medicine, 2016
- Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma2016
- N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesisCarcinogenesis, 2014
- Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosisJournal of Experimental & Clinical Cancer Research, 2009
- Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian menBJU International, 2006
- The effect of heavy metals on nicotinamideN-methyltransferase activityin vitro relating to Parkinson’s diseaseEnvironmental Health and Preventive Medicine, 2005
- Gene Silencing in Cancer in Association with Promoter HypermethylationNew England Journal of Medicine, 2003
- Racial Differences in Pancreatic Cancer: Comparison of Survival and Histologic Types of Pancreatic Carcinoma in Asians, Blacks, and Whites in the United StatesPancreas, 2000